Nov 3, 4:09 PM ET
Corcept Therapeutics reported third quarter 2026 revenue of $340.5 million, up 64 percent from the same period in 2025, and net income of $126.8 million, compared with $19.7 million a year earlier. The company reiterated its 2026 revenue guidance of $1.1 billion to $1.2 billion, and its Lifyorli ovarian cancer product contributed $91.4 million of the quarter's revenue.
- Q3 2026 revenue of $340.5 million vs. $207.6 million in Q3 2025; Korlym and authorized generic revenue was $249.1 million and Lifyorli revenue was $91.4 million
- Q3 2026 net income of $126.8 million, or $1.01 per diluted share, vs. $19.7 million, or $0.16 per diluted share, in Q3 2025
- 2026 revenue guidance of $1.1 billion to $1.2 billion reiterated; cash and investments rose to $662.3 million at September 30, 2026
- Relacorilant for Cushing's syndrome has a PDUFA date of December 17, 2026
Read the filing on SEC.gov ↗
Sep 23, 8:15 AM ET
Corcept Therapeutics said Sean Maduck, President of its Endocrinology division, will retire effective October 1, 2026, and Justin Gunn will succeed him. Maduck will stay on as a consultant under an agreement paying $57,000 per month, and the company said he did not resign because of any disagreement with the company. The filing does not include financial results or guidance changes, so the direct effect on shareholders is limited to the leadership change.
- Sean Maduck notified the board on September 22, 2026 of his decision to resign effective October 1, 2026.
- Maduck's consulting agreement runs through September 30, 2027, with a cash fee of $57,000 per month, and his outstanding stock options continue to vest.
- Justin Gunn joined Corcept in July 2024 as Vice President of Sales and Commercial Learning for the Oncology division and will report to CEO Joseph K. Belanoff, M.D.
Read the filing on SEC.gov ↗
Jul 29, 4:07 PM ET
Corcept Therapeutics reported second-quarter 2026 revenue of $256.1 million, up 32% from $194.4 million a year earlier, and raised its 2026 revenue guidance to $1.1-$1.2 billion. Net income rose to $43.0 million from $35.1 million, though operating expenses increased to $214.8 million from $167.8 million on Lifyorli launch spending and Cushing's syndrome investments.
- Q2 2026 revenue of $256.1 million, including $47.6 million from Lifyorli in its first quarter of availability
- Diluted net income per share of $0.36, compared with $0.29 in Q2 2025
- Operating expenses rose to $214.8 million from $167.8 million, driven by Lifyorli launch and Cushing's investments
- Six-month net income was $11.2 million, down from $55.7 million a year earlier; the FDA decision on the Cushing's NDA is expected by December 17, 2026
Read the filing on SEC.gov ↗
May 28, 4:04 PM ET
At its May 21, 2026 annual meeting, Corcept Therapeutics stockholders approved an amendment adding 8,000,000 shares to the 2024 Incentive Award Plan, which took effect that day. The filing also reports the election of eight directors and the ratification of Ernst & Young LLP as the independent auditor for fiscal 2026. The plan increase expands the shares available for equity awards, which can dilute existing holders.
- Stockholders approved the Amended 2024 Incentive Award Plan, adding 8,000,000 shares, with 53,163,364 votes for, 23,867,363 against and 263,730 abstaining.
- All eight director nominees were elected to serve until the 2027 annual meeting, including Joseph K. Belanoff, M.D., and David L. Mahoney.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026, with 92,656,473 votes for.
- In an advisory vote, stockholders approved named executive officer compensation, with 72,511,429 votes for and 4,560,385 against.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.